Want to see AU:RCE full AI Analyst Report?
Total Valuation
Recce Pharmaceuticals Ltd. has a market cap or net worth of AU$99.38M. The enterprise value is AU$124.87.
Market CapAU$99.38M
Enterprise ValueAU$124.87
Share Statistics
Recce Pharmaceuticals Ltd. has 305,770,080 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding305,770,080
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Recce Pharmaceuticals Ltd.’s return on equity (ROE) is 0.89 and return on invested capital (ROIC) is 238.75%.
Return on Equity (ROE)0.89
Return on Assets (ROA)-1.75
Return on Invested Capital (ROIC)238.75%
Return on Capital Employed (ROCE)2.97
Revenue Per Employee0.00
Profits Per Employee-1.87M
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Recce Pharmaceuticals Ltd. is ―. Recce Pharmaceuticals Ltd.’s PEG ratio is 0.18.
PE Ratio―
PS Ratio0.00
PB Ratio-7.00
Price to Fair Value-7.00
Price to FCF-11.77
Price to Operating Cash Flow-9.21
PEG Ratio0.18
Income Statement
In the last 12 months, Recce Pharmaceuticals Ltd. had revenue of 0.00 and earned -14.96M in profits. Earnings per share was -0.05.
Revenue0.00
Gross Profit-356.40K
Operating Income-23.16M
Pretax Income-23.84M
Net Income-14.96M
EBITDA-22.81M
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was -9.89M and capital expenditures -61.96K, giving a free cash flow of -9.95M billion.
Operating Cash Flow-9.89M
Free Cash Flow-9.95M
Free Cash Flow per Share-0.03
Dividends & Yields
Recce Pharmaceuticals Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.34
52-Week Price Change-24.10%
50-Day Moving Average0.36
200-Day Moving Average0.48
Relative Strength Index (RSI)37.45
Average Volume (3m)78.42K
Important Dates
Recce Pharmaceuticals Ltd. upcoming earnings date is Mar 1, 2027, TBA (Confirmed).
Last Earnings DateAug 31, 2026
Next Earnings DateMar 1, 2027
Ex-Dividend Date―
Financial Position
Recce Pharmaceuticals Ltd. as a current ratio of 0.44, with Debt / Equity ratio of -62.44%
Current Ratio0.44
Quick Ratio0.44
Debt to Market Cap0.09
Net Debt to EBITDA-0.34
Interest Coverage Ratio-13.96
Taxes
In the past 12 months, Recce Pharmaceuticals Ltd. has paid -8.88M in taxes.
Income Tax-8.88M
Effective Tax Rate0.37
Enterprise Valuation
Recce Pharmaceuticals Ltd. EV to EBITDA ratio is -5.47, with an EV/FCF ratio of -12.54.
EV to Sales0.00
EV to EBITDA-5.47
EV to Free Cash Flow-12.54
EV to Operating Cash Flow-12.62
Balance Sheet
Recce Pharmaceuticals Ltd. has AU$2.69M in cash and marketable securities with AU$10.44M in debt, giving a net cash position of -AU$7.75M billion.
Cash & Marketable SecuritiesAU$2.69M
Total DebtAU$10.44M
Net Cash-AU$7.75M
Net Cash Per Share-AU$0.03
Tangible Book Value Per Share-AU$0.06
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Recce Pharmaceuticals Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast42.51%